Open-Label Extension Study for Alzheimer’s Treatment Showed Disease Reversal in Nearly Half of Study Participants in Just Three Months

FOSTER CITY, Calif., March 28, 2023 /PRNewswire/ — TrueBinding, Inc.— a clinical-stage biotherapeutic company creating new and exciting molecules for applications in neurodegenerative and other disease areas with great unmet needs— today announced early results from an Open-Label…